Indication · Neurology & Neurosurgery
Acute ischemic stroke
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
264
Cleared or approved since 2000
PMA and De Novo
3
Higher-risk or first-of-kind devices
Breakthrough devices
6
Authorized through June 30, 2026
Recruiting device trials
146
888 device trials in all
Breakthrough-designated devices
- Millipede SystemPerfuze, Ltd. · 2026
5 more devices with a free account
Devices
261 devices via 510(k). PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- Penumbra System (Thunderbolt Aspiration Tubing)
Penumbra, Inc. · 510(k) · Catheter, Thrombus Retriever · newest 2026 · 24 decisions
59 more devices with a free account
Showing the first 60. Narrow by pathway, or open a device type below.
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
Recross Cardio, Inc.Not on our public-company list
NCT07172464 · 30 participants (planned) · Start Oct 9, 2025 · Primary completion Aug 2027
Device: Recross P3 Occluder (P3O) System · For: PFO; PFO - Patent Foramen Ovale; Cryptogenic Stroke and 2 more
Sites: Los Angeles, California; Gainsville, Florida; Boston, Massachusetts · 4 sites in all
887 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
- Catheter, Percutaneous, Neurovasculature (QJP)84
- Catheter, Thrombus Retriever (NRY)69
- Radiological Computer-Assisted Triage And Notification Software (QAS)54
- Guide, Wire, Catheter, Neurovasculature (MOF)36
- Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL)15
- Impedance Plethysmograph, Cranial (QAF)3
- Cranial Motion Measurement Device (POP)2
- Diagnostic Ultrasonic Transducer, Robotic (OQQ)1
Research
- Device studies on ischemic stroke across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.